Want to see AU:SOM full AI Analyst Report?
SOM Stock Chart & Stats
AU$0.56
AU$0.03(6.67%)
At close: 4:00 PM EST
AU$0.56
AU$0.03(6.67%)
Day’s Range― - ―
52-Week RangeAU$0.42 - AU$0.95
Previous CloseN/A
Volume51.81K
Average Volume (3M)705.41K
Market Cap
AU$98.90M
Enterprise ValueAU$159.83
Total Cash (Recent Filing)AU$18.03M
Total Debt (Recent Filing)AU$14.01M
Price to Earnings (P/E)―
Beta1.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding219,768,250
10 Day Avg. Volume159,446
30 Day Avg. Volume705,406
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.97
Price to Sales (P/S)1.24
P/FCF Ratio25.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.75Price Target Upside33.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendConsistent revenue growth (latest +11.22%) indicates expanding adoption of SomnoMed’s oral appliances across geographies and channels. Durable demand growth supports scale, improves fixed-cost absorption, and underpins longer-term margin and cash-generation improvements if sustained.
High Gross MarginsA ~60% gross margin reflects strong product economics and pricing power for custom oral appliances. Sustained high gross margins create a buffer to absorb SG&A and R&D investment, enabling reinvestment for distribution expansion while protecting profitability potential long term.
Strong Cash Generation ImprovementA >562% improvement in free cash flow and positive operating cash flow despite accounting losses shows the business converts sales to cash. Durable cash generation reduces refinancing risk, funds growth initiatives and product development, and supports a conservative balance sheet strategy.
Bears Say
Persistent UnprofitabilityOngoing negative net profit and EBIT margins show SomnoMed has not yet translated revenue growth and gross margins into operating profitability. Persistent losses can require continued investment or capital raises, limiting returns to shareholders until structural profitability is achieved.
Negative Return On EquityA negative ROE despite low leverage (debt-to-equity 0.17) indicates inefficient capital use and weak net income conversion. This structural weakness suggests scaling revenues alone may be insufficient without improved operating leverage or cost control to deliver shareholder returns.
Dependence On Clinical Workflow & ReimbursementRevenue depends on physician diagnosis, dentist fittings and reimbursement policies. Structural adoption versus CPAP and country-by-country reimbursement create a durable constraint on addressable market growth and adoption pace, making sales sensitive to clinical referral patterns and policy changes.
Somnomed Limited News
SOM FAQ
What was Somnomed Limited’s price range in the past 12 months?
Somnomed Limited lowest share price was AU$0.42 and its highest was AU$0.94 in the past 12 months.
What is Somnomed Limited’s market cap?
Somnomed Limited’s market cap is AU$98.90M.
When is Somnomed Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Somnomed Limited’s earnings last quarter?
Currently, no data Available
Is Somnomed Limited overvalued?
According to Wall Street analysts Somnomed Limited’s price is currently Undervalued.
Does Somnomed Limited pay dividends?
Somnomed Limited does not currently pay dividends.
What is Somnomed Limited’s EPS estimate?
Somnomed Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Somnomed Limited have?
Somnomed Limited has 219,768,250 shares outstanding.
What happened to Somnomed Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Somnomed Limited?
Currently, no hedge funds are holding shares in AU:SOM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Somnomed Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.75 (33.93% Upside)
AU$0.75 (33.93% Upside)
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.75%
Trailing 12-Months
Company Description
Somnomed Limited
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
SOM Stock 12 Month Forecast
Average Price Target
AU$0.75
▲(33.93% Upside)